In this episode of Denatured, sponsored by SK pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode,...
As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts...
The operational challenges of making patient-specific cell therapies require careful consideration. Choosing the manufacturing model that fits the healthcare infrastructure, the logistical requirements, and the market...
AstraZeneca researchers show that automated microscale chromatography can generate process-characterization insights comparable to traditional bench-scale systems, potentially giving bioprocess developers a faster, material-sparing route to robust...
The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.
The new facility expands the company’s capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based...
Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up its internal manufacturing capabilities.
A more coherent approach: a peptide-mapping LC-HRMS (liquid chromatography-high resolution mass spectrometry) workflow that can identify and monitor multiple product quality attributes, including selected critical quality...
Contract development and manufacturing organizations looking to do business with biopharmas include Lonza, which has more than 30 sites, and Samsung Biologics, which recently announced a...
The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It...
Scan to Read